NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 11 min ago

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

Mon, 08/05/2019 - 11:42
Funding Opportunity PAR-19-328 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Clinical trials supported by this FOA include Phase II and above clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.
Categories: Science RSS Feeds

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

Mon, 08/05/2019 - 11:28
Funding Opportunity PAR-19-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-NNN) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The DCC application must be specific for the clinical trial being proposed in the collaborating CCC. The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.
Categories: Science RSS Feeds

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

Mon, 08/05/2019 - 11:28
Funding Opportunity PAR-19-329 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-19-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.
Categories: Science RSS Feeds

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Required

Mon, 08/05/2019 - 04:52
Funding Opportunity PAR-19-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award.
Categories: Science RSS Feeds

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, R44) Clinical Trial Not Allowed

Mon, 08/05/2019 - 04:51
Funding Opportunity PAR-19-334 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the SBC is expected to maintain oversight and management of the R and D throughout the award. Clinical trials not accepted under this FOA.
Categories: Science RSS Feeds

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed

Mon, 08/05/2019 - 04:51
Funding Opportunity PAR-19-333 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award.
Categories: Science RSS Feeds

NIH Offers Assistance to Phase II HHS SBIR and STTR Awardees through the NIH Commercialization Accelerator Program (CAP) 2019-2020

Fri, 08/02/2019 - 02:01
Notice NOT-OD-19-129 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)

Thu, 08/01/2019 - 00:38
Funding Opportunity PAR-19-327 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.
Categories: Science RSS Feeds

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)

Wed, 07/31/2019 - 11:02
Funding Opportunity RFA-ES-19-011 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.
Categories: Science RSS Feeds

Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed)

Wed, 07/31/2019 - 10:41
Funding Opportunity RFA-AG-20-035 from the NIH Guide for Grants and Contracts. This FOA will use the NIH Resource-Related Research Project (R24) mechanism to facilitate the development of research networks to advance research on the basic biology of aging in health disparities. The infrastructure-building aspect of this FOA will be to establish collaborations for subsequent research on the biology of aging underlying health disparities. The intention is to provide a platform for discovery and pilot projects to establish feasibility of novel approaches to be used by these collaborations. For this FOA, the key human population feature of health disparities is accelerated aging.
Categories: Science RSS Feeds

Catalyst Award In Diabetes, Endocrinology and Metabolic Diseases (DP1 Clinical Trial Not Allowed)

Wed, 07/31/2019 - 10:24
Funding Opportunity RFA-DK-19-014 from the NIH Guide for Grants and Contracts. The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering andtransformational studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.
Categories: Science RSS Feeds

Notice of Clarification for NOT-MH-19-033, "Notice of Data Sharing Policy for the National Institute of Mental Health"

Wed, 07/31/2019 - 10:09
Notice NOT-MH-19-041 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Pages